Imaging Technique Measures Skin Fibrosis in Sclerosis
Researchers find that spatial frequency domain imaging can track disease progression in systemic sclerosis patients.
Updated on Oct. 20, 2026 in Arthritis
Live Poll
Do you trust non-invasive imaging as a reliable substitute for traditional physical skin exams?
A new study published in The Lancet Rheumatology suggests that spatial frequency domain imaging (SFDI) could serve as a reliable tool for monitoring skin involvement in systemic sclerosis. The imaging technique successfully correlates with traditional clinical assessments and skin biopsies.
Why it matters
Identifying effective, non-invasive biomarkers is critical for improving patient monitoring and advancing clinical trials for systemic sclerosis. This imaging method offers a standardized approach to quantify skin fibrosis, which is a hallmark of the condition.
The study involved 49 systemic sclerosis participants and 25 controls, with researchers recording correlation ranges of -0.38 to -0.48 between SFDI and modified Rodnan skin scores. Correlations between SFDI and histological fibrosis ranged from -0.34 to -0.52.
The players
The Lancet Rheumatology
This is a monthly peer-reviewed medical journal that publishes original research and reviews focused on rheumatic diseases.
The details
Participants underwent SFDI, modified Rodnan skin score assessments, and forearm biopsies to determine the accuracy of the imaging technique. The study found that diffuse reflectance and reduced scattering coefficients were significantly lower in the systemic sclerosis cohort compared to controls.
Timeline
October 14, 2026: The study was published online in The Lancet Rheumatology.
October 20, 2026: Results were reported by HealthDay News.
Health Landscape
By correlating SFDI with the modified Rodnan skin score, this study bridges the gap between traditional clinical scoring and modern non-invasive imaging. It marks an attempt to move beyond subjective manual assessments toward quantitative, objective metrics in rheumatology.
This imaging development could eventually lead to more accurate, non-invasive monitoring for patients with systemic sclerosis. By reducing the reliance on painful skin biopsies, it may improve the patient experience during routine check-ups and clinical research visits.
The takeaway
This research provides a promising path for standardizing how physicians measure the skin health of patients with systemic sclerosis. Future clinical trials may benefit from using this imaging technology to track the efficacy of potential new treatments.
Further reading
For more information on current treatment methods, visit the Arthritis section.
Live Poll
Do you trust non-invasive imaging as a reliable substitute for traditional physical skin exams?
